Tumor News and Research

RSS

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.

21 Jan 2016

Paradigm, UnitedHealthcare sign contractual agreement for coverage of PCDx

Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients today announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx.

21 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Melanoma is the most dangerous and lethal form of skin cancer. But just how long will a patient survive following the removal of a melanoma tumor? A more definitive answer to that question could come from new studies at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual's survival and determine which patients require closer monitoring in the years following surgery.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Amorphous iron nanoparticles have potential to kill tumor cells

Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.

20 Jan 2016

Diabetes drug fails to show any benefit against pancreatic cancer

A diabetes drug that showed promise in previous studies as an anti-cancer treatment failed to show any benefit in a UNC Lineberger Comprehensive Cancer Center-led study that used pancreatic cancer tissue samples to test sensitivity to the drug.

20 Jan 2016

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.

20 Jan 2016

Animal antibodies help identify diseased cells during immunohistology procedures

We all know it from biology lessons at school: Antibodies help us to ward off disease and are essential components of our immune system. What many people do not know is that physicians and scientists use animal antibodies to identify diseased or mutated cells.

20 Jan 2016

New method could improve accurate diagnosis of ovarian cancer before surgery

In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99% of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers.

20 Jan 2016

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

19 Jan 2016

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program.

18 Jan 2016

Researchers reveal biological connection between obesity and colorectal cancer risk

Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood. Now, a research team led by investigators at Thomas Jefferson University has revealed the biological connection, and in the process, has identified an approved drug that might prevent development of the cancer.

18 Jan 2016

Rockefeller University researchers identify new mechanism involved in early stem cell development

Stem cells work throughout our lives as a sort of handyman, repairing damaged tissues and renewing some normal ones, like the skin we shed. Scientists have come to understand much about how stem cells function when we are adults, but less is known about where these stem cells come from to begin with, as an embryo is developing.

18 Jan 2016

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor.

18 Jan 2016

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina.

18 Jan 2016

University of Copenhagen researchers develop new cell line to investigate brain drugs

Researchers from the Department of Pharmacy at the University of Copenhagen have developed a cell line, which may be used to investigate new drugs and help predict whether they are able to enter the brain.

18 Jan 2016

MGH researchers find how metformin drug prevents progression of pancreatic cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of the diabetes drug metformin to inhibit the progression of pancreatic cancer.

17 Jan 2016

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself.

13 Jan 2016

Tumor News and Research

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Paradigm, UnitedHealthcare sign contractual agreement for coverage of PCDx

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Immunotherapy could be the future of cancer treatments

Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Amorphous iron nanoparticles have potential to kill tumor cells

Diabetes drug fails to show any benefit against pancreatic cancer

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Animal antibodies help identify diseased cells during immunohistology procedures

New method could improve accurate diagnosis of ovarian cancer before surgery

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

Researchers reveal biological connection between obesity and colorectal cancer risk

Rockefeller University researchers identify new mechanism involved in early stem cell development

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

University of Copenhagen researchers develop new cell line to investigate brain drugs

MGH researchers find how metformin drug prevents progression of pancreatic cancer

Researchers reveal totally new biological mechanism that underlies cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News